{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:07:46Z","timestamp":1792058866179,"version":"4.4.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.canlet.2021.12.035","type":"journal-article","created":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T20:57:26Z","timestamp":1641243446000},"page":"100-111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["An orally available small molecule BCL6 inhibitor effectively suppresses diffuse large B cell lymphoma cells growth in vitro and in vivo"],"prefix":"10.1016","volume":"529","author":[{"given":"Yajing","family":"Xing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weikai","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiuqing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxia","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaoran","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiansen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peili","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8079-8638","authenticated-orcid":false,"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guixue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huangan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cili","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengfang","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenliang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2021.12.035_bib1","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nri3814","article-title":"Germinal centres and B cell lymphomagenesis","volume":"15","author":"Basso","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2021.12.035_bib2","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/imr.12755","article-title":"Germinal center-derived lymphomas: the darkest side of humoral immunity","volume":"288","author":"Mlynarczyk","year":"2019","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.canlet.2021.12.035_bib3","first-page":"443","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.canlet.2021.12.035_bib4","series-title":"Hematology Am Soc Hematol Educ Program, 2016","first-page":"366","article-title":"Diffuse large B-cell lymphoma: R-CHOP failure-what to do?","author":"Coiffier","year":"2016"},{"key":"10.1016\/j.canlet.2021.12.035_bib5","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2021.12.035_bib6","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2021.12.035_bib7","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/14728222.2018.1420782","article-title":"BCL6 as a therapeutic target for lymphoma","volume":"22","author":"Leeman-Neill","year":"2018","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.canlet.2021.12.035_bib8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2010.08420.x","article-title":"The role of BCL6 in lymphomas and routes to therapy","volume":"152","author":"Wagner","year":"2011","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2021.12.035_bib9","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1586\/17474086.2013.826928","article-title":"Targeting BCL6 in diffuse large B-cell lymphoma: what does this mean for the future treatment?","volume":"6","author":"Cerchietti","year":"2013","journal-title":"Expet Rev. Hematol."},{"key":"10.1016\/j.canlet.2021.12.035_bib10","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1126\/science.8235596","article-title":"Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma","volume":"262","author":"Ye","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.canlet.2021.12.035_bib11","doi-asserted-by":"crossref","first-page":"10762","DOI":"10.1073\/pnas.94.20.10762","article-title":"Corepressor SMRT binds the BTB\/POZ repressing domain of the Laz3\/BCL6 oncoprotein","volume":"94","author":"Dhordain","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2021.12.035_bib12","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S1097-2765(03)00454-4","article-title":"Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain","volume":"12","author":"Ahmad","year":"2003","journal-title":"Mol. Cell."},{"key":"10.1016\/j.canlet.2021.12.035_bib13","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1101\/gad.14.14.1810","article-title":"BCoR, a novel corepressor involved in BCL-6 repression","volume":"14","author":"Huynh","year":"2000","journal-title":"Genes Dev."},{"key":"10.1016\/j.canlet.2021.12.035_bib14","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/ni1478","article-title":"Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR","volume":"8","author":"Ranuncolo","year":"2007","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2021.12.035_bib15","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.bcmd.2008.02.003","article-title":"BCL6 represses CHEK1 and suppresses DNA damage pathways in normal and malignant B-cells","volume":"41","author":"Ranuncolo","year":"2008","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.canlet.2021.12.035_bib16","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.1182\/blood-2008-12-193037","article-title":"The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL","volume":"113","author":"Ci","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2021.12.035_bib17","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/nature03147","article-title":"The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells","volume":"432","author":"Phan","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2021.12.035_bib18","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.4049\/jimmunol.173.2.1158","article-title":"Direct repression of prdm1 by Bcl-6 inhibits plasmacytic differentiation","volume":"173","author":"Tunyaplin","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2021.12.035_bib19","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1182\/blood-2002-11-3387","article-title":"Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma","volume":"101","author":"Pasqualucci","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2021.12.035_bib20","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1073\/pnas.0611399104","article-title":"Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas","volume":"104","author":"Polo","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2021.12.035_bib21","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ccr.2005.03.037","article-title":"Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice","volume":"7","author":"Cattoretti","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2021.12.035_bib22","doi-asserted-by":"crossref","first-page":"14198","DOI":"10.1073\/pnas.0406138101","article-title":"The human BCL6 transgene promotes the development of lymphomas in the mouse","volume":"101","author":"Baron","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2021.12.035_bib23","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1182\/blood-2008-07-168773","article-title":"A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo","volume":"113","author":"Cerchietti","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2021.12.035_bib24","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1172\/JCI42869","article-title":"BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy","volume":"120","author":"Cerchietti","year":"2010","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2021.12.035_bib25","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1172\/JCI85795","article-title":"Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma","volume":"126","author":"Cardenas","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2021.12.035_bib26","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.1021\/acs.jmedchem.7b00313","article-title":"Discovery of a B-cell lymphoma 6 protein-protein interaction inhibitor by a biophysics-driven fragment-based approach","volume":"60","author":"Kamada","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.canlet.2021.12.035_bib27","doi-asserted-by":"crossref","first-page":"4386","DOI":"10.1021\/acs.jmedchem.7b00359","article-title":"Discovery of pyrazolo[1,5-a]pyrimidine B-cell lymphoma 6 (BCL6) binders and optimization to high affinity macrocyclic inhibitors","volume":"60","author":"McCoull","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.canlet.2021.12.035_bib28","doi-asserted-by":"crossref","first-page":"7573","DOI":"10.1021\/acs.jmedchem.8b00040","article-title":"Identification of thiourea-based inhibitors of the B-cell lymphoma 6 BTB domain via NMR-based fragment screening and computer-aided drug design","volume":"61","author":"Cheng","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.canlet.2021.12.035_bib29","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1016\/j.celrep.2017.08.081","article-title":"Chemically induced degradation of the oncogenic transcription factor BCL6","volume":"20","author":"Kerres","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2021.12.035_bib30","doi-asserted-by":"crossref","first-page":"4876","DOI":"10.1016\/j.bmc.2017.07.037","article-title":"Discovery of a novel B-cell lymphoma 6 (BCL6)-corepressor interaction inhibitor by utilizing structure-based drug design","volume":"25","author":"Yasui","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.canlet.2021.12.035_bib31","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1021\/jm201243p","article-title":"Privileged scaffolds or promiscuous binders: a comparative study on rhodanines and related heterocycles in medicinal chemistry","volume":"55","author":"Mendgen","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.canlet.2021.12.035_bib32","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1517\/17460441.2012.688743","article-title":"Rhodanine as a scaffold in drug discovery: a critical review of its biological activities and mechanisms of target modulation","volume":"7","author":"Tomasic","year":"2012","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.canlet.2021.12.035_bib33","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/dvg.22964","article-title":"Broad-complex, tramtrack, and bric-a-brac (BTB) proteins: critical regulators of development","volume":"54","author":"Chaharbakhshi","year":"2016","journal-title":"Genesis"},{"key":"10.1016\/j.canlet.2021.12.035_bib34","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.tcb.2006.09.003","article-title":"POZ for effect--POZ-ZF transcription factors in cancer and development","volume":"16","author":"Kelly","year":"2006","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.canlet.2021.12.035_bib35","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1128\/MCB.22.6.1804-1818.2002","article-title":"Critical residues within the BTB domain of PLZF and Bcl-6 modulate interaction with corepressors","volume":"22","author":"Melnick","year":"2002","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2021.12.035_bib36","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s00216-003-2101-0","article-title":"Present and future of surface plasmon resonance biosensors","volume":"377","author":"Homola","year":"2003","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.canlet.2021.12.035_bib37","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/ni.2543","article-title":"Lineage-specific functions of Bcl-6 in immunity and inflammation are mediated by distinct biochemical mechanisms","volume":"14","author":"Huang","year":"2013","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2021.12.035_bib38","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1158\/2159-8290.CD-16-1189","article-title":"BCL6 antagonizes NOTCH2 to maintain survival of human follicular lymphoma cells","volume":"7","author":"Valls","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2021.12.035_bib39","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1007\/s11427-015-4919-z","article-title":"Mechanisms of action of BCL6 during germinal center B cell development","volume":"58","author":"Huang","year":"2015","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.canlet.2021.12.035_bib40","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/nm1134","article-title":"Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells","volume":"10","author":"Polo","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2021.12.035_bib41","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.immuni.2011.03.025","article-title":"Bcl6 protein expression shapes pre-germinal center B cell dynamics and follicular helper T cell heterogeneity","volume":"34","author":"Kitano","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2021.12.035_bib42","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ccell.2016.07.006","article-title":"EZH2 and BCL6 cooperate to assemble CBX8-BCOR complex to repress bivalent promoters, mediate germinal center formation and lymphomagenesis","volume":"30","author":"Beguelin","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2021.12.035_bib43","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1182\/blood-2018-02-831438","article-title":"PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival","volume":"132","author":"Lu","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2021.12.035_bib44","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1158\/1078-0432.CCR-16-2071","article-title":"The expanding role of the BCL6 oncoprotein as a cancer therapeutic target","volume":"23","author":"Cardenas","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2021.12.035_bib45","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1073\/pnas.1609758114","article-title":"BCL6 promotes glioma and serves as a therapeutic target","volume":"114","author":"Xu","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2021.12.035_bib46","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/onc.2014.61","article-title":"The transcriptional modulator BCL6 as a molecular target for breast cancer therapy","volume":"34","author":"Walker","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2021.12.035_bib47","first-page":"255","article-title":"BCL6 is a negative prognostic factor and exhibits pro-oncogenic activity in ovarian cancer","volume":"5","author":"Wang","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.canlet.2021.12.035_bib48","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1158\/0008-5472.CAN-15-3052","article-title":"Combination therapy targeting BCL6 and phospho-STAT3 defeats intratumor heterogeneity in a subset of non-small cell lung cancers","volume":"77","author":"Deb","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2021.12.035_bib49","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nature09883","article-title":"BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition","volume":"473","author":"Duy","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2021.12.035_bib50","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1038\/onc.2017.85","article-title":"Interferon gamma is a STAT1-dependent direct inducer of BCL6 expression in imatinib-treated chronic myeloid leukemia cells","volume":"36","author":"Madapura","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2021.12.035_bib51","first-page":"6953506","article-title":"Knockdown of BCL6 inhibited malignant phenotype and enhanced sensitivity of glioblastoma cells to TMZ through AKT pathway","author":"Song","year":"2018","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.canlet.2021.12.035_bib52","first-page":"5240","article-title":"BCL6 promotes the methotrexate-resistance by upregulating ZEB1 expression in children with acute B lymphocytic leukemia","volume":"22","author":"Wu","year":"2018","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.canlet.2021.12.035_bib53","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1158\/2159-8290.CD-17-1444","article-title":"BCL6 evolved to enable stress tolerance in vertebrates and is broadly required by cancer cells to adapt to stress","volume":"9","author":"Fernando","year":"2019","journal-title":"Cancer Discov."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383521006583?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383521006583?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T16:01:56Z","timestamp":1759593716000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383521006583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":53,"alternative-id":["S0304383521006583"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2021.12.035","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-820765\/v1","asserted-by":"object"}]},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An orally available small molecule BCL6 inhibitor effectively suppresses diffuse large B cell lymphoma cells growth in vitro and in vivo","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2021.12.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}